Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
10x Genomics ( (TXG) ) has shared an update.
10x Genomics reported a slight decrease in third-quarter revenue to $151.7 million, primarily due to lower instrument sales, but noted strong performance from consumables. Despite challenges from sales restructuring and cautious customer spending, the company launched new products like GEM-X Flex and Chromium Xo to drive cost-effective research. CEO Serge Saxonov expressed confidence in reaching more customers and achieving long-term growth despite lowering the annual revenue forecast.
For an in-depth examination of TXG stock, go to TipRanks’ Stock Analysis page.